Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease

By afschroeder • March 5, 2026

Curigliano G, Hu X, Dent R, Yonemori K, Barrios CH, Pierga JY, Puglisi F, Ferrero JM, Jung KH, Bagegni NA, Collignon J, Gil-Gil M, Wu X, Andrzejuk-Ćwik A, Schwaederle M, Anand S, Bardia A. Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease. Ann Oncol. 2026 Mar 2:S0923-7534(26)00071-2. doi: 10.1016/j.annonc.2026.02.015. Epub ahead of print. PMID: 41780642.

Tags: burden of disease, endocrine resistance, Hematology/Oncology, metastatic breast cancer, Publications, subgroup analysis, time to progression, trastuzumab deruxtecan

Related Posts

A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer

Johnson ML, Smit EF, Felip E, Ramalingam SS, Ahn MJ, Tsao A, Johnson BE, Offin M, Hussein M, Dagogo-Jack I, Goldman JW, Clarke JM, Negrao[...]

Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial

Wainberg ZA, Manji GA, Bahary N, Ulahannan SV, Pant S, Spigel DR, Uboha NV, Oberstein PE, Saeed A, Beagle B, Kim JY, Wang N, Weeder[...]

Advancing precision health discovery in a genetically diverse health system

Haas R, Margolis MP, Wei A, Yamaguchi TN, Feng J, Tran T, Tozzo V, Queen KJ, Mootor MFE, Patil V, Broudy ME, Tung P, Alam[...]